C
Coeptis Therapeutics Holdings, Inc. (COEP)
NCM – Real Time Price. Currency in USD
16.40
+16.40 (0.00%)
At close: Apr 24, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
16.40
+16.40 (0.00%)
At close: Apr 24, 2026, 4:00 PM EDT
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company’s product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
| Name | Position |
|---|---|
| Mr. David Mehalick | Co-Founder, Chairman of the Board, CEO & President |
| Date | Type | Document |
|---|---|---|
| 2026-05-01 | 8-K | zsquared_8k.htm |
| 2026-04-30 | 8-K | zsquared_8k.htm |
| 2026-04-28 | 8-K | zsquared_8k.htm |
| 2026-04-24 | 8-K | coeptis_8k.htm |
| 2026-04-08 | 8-K | coeptis_8k.htm |
| 2026-03-19 | 10-K | coeptis_i10k-123125.htm |
| 2026-02-12 | 8-K | coeptis_8k.htm |
| 2026-02-04 | 8-K | coeptis_8k.htm |
| 2026-01-16 | 8-K | coeptis_8k.htm |
| 2025-12-22 | S-4/A | coeptis_s4a5.htm |